Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry
- Graham Simmons,
- Jacqueline D. Reeves,
- Andrew J. Rennekamp,
- Sean M. Amberg,
- Andrew J. Piefer, and
- Paul Bates*
- Department of Microbiology, University of Pennsylvania School of Medicine, 225 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104
-
Edited by Peter S. Kim, Merck Research Laboratories, West Point, PA (received for review October 6, 2003)
Abstract
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is a rapidly emerging pathogen with potentially serious consequences for public health. Here we describe conditions that result not only in the efficient expression of the SARS-CoV spike (S) protein on the surface of cells, but in its incorporation into lentiviral particles that can be used to transduce cells in an S glycoprotein-dependent manner. We found that although some primate cell lines, including Vero E6, 293T and Huh-7 cells, could be efficiently transduced by SARS-CoV S glycoprotein pseudoviruses, other cells lines were either resistant or very poorly permissive to virus entry. Infection by pseudovirions could be inhibited by several lysosomotropic agents, suggesting a requirement for acidification of endosomes for efficient S-mediated viral entry. In addition, we were able to develop a cell–cell fusion assay that could be used to monitor S glycoprotein-dependent membrane fusion. Although proteolysis did not enhance the infectivity of cell-free pseudovirions, trypsin activation is required for cell–cell fusion. Additionally, there was no apparent pH requirement for S glycoprotein-mediated cell–cell fusion. Together, these studies describe important tools that can be used to study SARS-CoV S glycoprotein structure and function, including approaches that can be used to identify inhibitors of the entry of SARS-CoV into target cells.
Footnotes
-
↵ * To whom correspondence should be addressed. E-mail: pbates{at}mail.med.upenn.edu.
-
This paper was submitted directly (Track II) to the PNAS office.
-
Abbreviations: SARS, severe acute respiratory syndrome; SARS-CoV, SARS-associated coronavirus; S, spike protein; MHV, mouse hepatitis virus; β-gal, β-galactosidase; HA, hemagglutinin; luc, luciferase; CMV, cytomegalovirus; FFU, focus-forming unit; VSV, vesicular stomatitis virus.
- Copyright © 2004, The National Academy of Sciences





